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Abstract
Background: The nerve growth factor (NGF) receptor tyrosine-kinase TrkA is a well-known determinant of the
melanocytic lineage, through modulation of the MAPK and AKT cascades. While TrkA gene is frequently rearranged
in cancers, its involvement in malignant melanoma (MM) development is still unclear.
Methods: We analyzed a dataset of primary cutaneous MM (n = 31) by array comparative genomic hybridization
(aCGH), to identify genomic amplifications associated with tumor progression. The analysis was validated by
genomic quantitative PCR (qPCR) on an extended set of cases (n = 64) and the results were correlated with the
clinical outcome. To investigate TrkA molecular pathways and cellular function, we generated inducible activation
of the NGF-TrkA signaling in human MM cell lines.
Results: We identified amplification of 1q23.1, where the TrkA locus resides, as a candidate hotspot implicated in
the progression of MM. Across 40 amplicons detected, segmental amplification of 1q23.1 showed the strongest
association with tumor thickness. By validation of the analysis, TrkA gene amplification emerged as a frequent event
in primary melanomas (50 % of patients), and correlated with worse clinical outcome. However, experiments in cell
lines revealed that induction of the NGF-TrkA signaling produced a phenotype of dramatic suppression of cell
proliferation through inhibition of cell division and pronounced intracellular vacuolization, in a way straightly
dependent on NGF activation of TrkA. These events were triggered via MAPK activity but not via AKT, and involved
p21cip1 protein increase, compatibly with a mechanism of oncogene-induced growth arrest.
Conclusions: Taken together, our findings point to TrkA as a candidate oncogene in MM and support a model in
which the NGF-TrkA-MAPK pathway may mediate a trade-off between neoplastic transformation and adaptive
anti-proliferative response.
Keywords: TrkA (NTRK1), Genomic amplification, Malignant melanoma, Oncogene-induced growth arrest, p21cip1
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Background
The neurotrophic tyrosine kinase receptor type 1
(NTRK1) or TRK1-transforming tyrosine kinase protein
(TrkA) is encoded in humans by the NTRK1 gene,
located in the chromosome region 1q23.1. TrkA specif-
ically mediates the multiple effects of the nerve growth
factor (NGF) signaling through receptor autophosphoryl-
ation and downstream induction of the mitogen-activated
protein kinase (MAPK) and protein kinase B (PKB/AKT)
pathways [1]. Although ubiquitously expressed, TrkA is
pivotal in mediating survival and differentiation of
neuroectoderm-derived cells, as neurons and melanocytes
[2]. During both development and adult life, overall levels
of NGF determine a balance between cell proliferation
and apoptosis of target cells [3]. These effects are usually
modulated by the p75 neurotrophin receptor (p75NTR),
an accessory receptor of TrkA that, by communicating
through convergence of signal transduction, can increase
the response to NGF or can signal by its own alternative
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function [3]. Given the complexity of this signaling and
the dual biological role of the NGF-TrkA axis in modulat-
ing either pro-survival or pro-apoptotic responses, regula-
tion of malignant transformation by the NGF pathway is
not completely understood. To date, TrkA signaling has
been intensively dissected for tumors of the neuroectoder-
mal lineage like neuroblastomas where, although TrkA is
overexpressed through genomic rearrangements and can
contribute to tumor onset, it seems to have a protective
effect against later unfavorable outcome [4]. However,
probably as a consequence of its predominant function in
stimulating cell proliferation, deregulation of the TrkA
pathway is common in cancers [5]. In this context,
chromosomal translocation of region 1q23.1 is known as
the major mechanism in oncogenic activation of TrkA,
being observed in several cancer types [6].
The fact that NGF and other neurotrophins are re-
quired for regulating melanocyte fate [7] underlines the
importance of Trk family members in the skin [8] and
poses the basis for investigating their activity in malig-
nancy onset and progression. However, very little is
known about the molecular function of Trk receptors in
melanocyte biology, and the exact mechanisms by which
the NGF-TrkA signaling may act in melanocytic disor-
ders remain largely unknown. Cutaneous malignant mel-
anoma (MM) is a deadly cancer of melanocyte origin,
for which conventional therapies become ineffective
once the tumor metastasizes [9]. In particular, a large
proportion of primary MMs harbors alterations in the
BRAF kinase that lead to the constitutive activation of
the MAPK pathway [10]. But, despite its aggressive be-
havior, MM is a typical example of tumor where hyper-
activation of MAPK signaling may induce a strong
negative feedback, resulting in reduction of the mito-
genic stimulus [11]. This mechanism is evident in benign
nevi, where a growth arrest program is operated by
oncogenic BRAF [12]. The natural propensity of melano-
cytic cells to elicit a physiological protective response
against neoplastic progression is exploited as a key factor
for clinical treatment of MM [13]. Hence, the identifica-
tion of pathways that regulate melanomagenesis should
serve for the development of novel therapeutic
modalities.
Recent advancements in microarray technologies have
revealed the complexity of genomic rearrangements oc-
curring in MM [14], with profound patterns of copy
number alterations (CNAs) that can arise already at its
early stages [15]. However, the discovery of specific
driver genes and the accurate profiling of genomic muta-
tions and CNAs in MM have been mainly based on MM
cell lines derived from metastatic samples [16, 17] or
have included a restricted cohort of clinical primary tu-
mors [18], limiting the detection of novel candidate al-
terations that may originate in the primary MM.
Although oncogenic activation of TrkA through
kinase-domain fusion has been recently observed in spit-
zoid melanoma-like lesions [19] and region 1q23.1 is
gained or amplified in a variety of other cancers [20, 21],
acquisition of TrkA genomic amplification in MM has
never been reported. In this study, we identify amplifica-
tion of TrkA as a candidate locus for melanomagenesis
in a subset of primary MM clinical samples, previously
analyzed by array comparative genomic hybridization
(aCGH) [15]. Subsequent experiments in MM cell lines
upon conditional activation of NGF-TrkA signaling re-
veal that, while TrkA is amplified in MM and may act as
an oncogene via the AKT pathway, it can also mediate
an oncogene-induced type of proliferation arrest via
MAPK activity and p21cip1 induction. This effect may
suggest a role of TrkA in coupling with the MAPK path-
way to promote susceptibility of MM cells to physio-
logical anti-oncogenic protection.
Methods
Tumor specimens from patients
We collected 64 formalin-fixed and paraffin-embedded
(FFPE) samples of primary cutaneous MM from the Sur-
gical Pathology Unit of the S. Chiara Hospital in Trento,
Italy. The study was approved by the Research Ethics
Committee for Clinical Experimentation of the Trentino
Public Healthcare Agency, Italy, and each patient signed
formal written informed consent for sampling and re-
search. Samples were diagnosed by expert pathologists
(SB and MB), according to the classification system of
the American Joint Committee on Cancer [22]. Clinical
features of the primary MMs and patients’ follow-up
data are summarized in Additional file 1: Table S1. The
sample ID indicated in any of the tables cannot be linked
back to any of the patients.
Cell lines
MM cell lines SK-MEL-28 and G-361 were a gift of
Alberto Inga (CIBIO, University of Trento, Italy) and
were originally obtained from the ICLC Interlab Cell
Line Collection (Istituto Nazionale per la Ricerca sul
Cancro, Genova, Italy). SK-MEL-28 cells were grown in
DMEM supplemented with 10 % fetal bovine serum
(FBS), 2 mM L-Glutamine, 1 % non-essential amino
acids, penicillin, and streptomycin. G-361 cells were cul-
tured in EMEM, supplemented with 10 % FBS, 2 mM L-
Glutamine, 1 % non-essential amino acids, penicillin,
and streptomycin. SK-MEL-28-TrkA and G-361-TrkA or
SK-MEL-28-E and G-361-E, were obtained by lentiviral
infection with TrkA-containing plasmid or empty vector,
respectively, and were maintained in the same culture
medium as the original stock.
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Genome profiling of clinical samples
Genomic copy number aCGH profiles of 31 MM sam-
ples, available as series GSE45354, at Gene Expression
Omnibus (GEO) repository (http://www.ncbi.nlm.nih.-
gov/geo/), were analyzed as previously described [15]. In
brief, the array CGH was performed using the Agilent
8x60K human CGH oligo microarray chip (Agilent
Technologies, Santa Clara, CA; 021924 SurePrint G3
Human CGH 8x60K Microarray, cat. G4450A), mapped
to the human genome (USCS genome browser Human,
Feb. 2009, GRCh37/hg19). The scanned microarray TIFF
images were acquired with the Agilent DNA Microarray
Scanner G2505C, by the manufacturer’s software (Agi-
lent ScanControl 8.1.3), and analyzed using the Agilent
Feature Extraction Software version 10.7.7.1. The ana-
lysis of raw aCGH data was then conducted via the R
environment for statistical computing (http://www.r-
project.org/) using packages provided by the Bioconduc-
tor library (http://www.bioconductor.org/). Hotspots of
minimal common regions of amplification were defined
as the minimal regions of overlap shared by at least
three samples with a maximum length of 2.5 Mb [20].
DNA extraction from clinical samples and genomic
real-time quantitative PCR
Genomic DNA (gDNA) was isolated from all FFPE arch-
ival samples using an optimized DNA isolation protocol
based on a Qiagen extraction kit (#51306; Qiagen), as
previously detailed [15]. Quantitative PCR (qPCR) valid-
ation of genomic copy number was performed by using
the laminin alpha 1 (LAMA1) gene, located in 18p11.31,
as reference gene, since this locus showed absence of
CNAs in 97 % of cases from our aCGH dataset. As dip-
loid calibrator, a pooled FFPE gDNA of 10 healthy pa-
tients with inflammation of the vermiform appendix was
used. Two benign nevi were used as an additional dip-
loid control. The reaction was performed by using the
commercially available FAM-labeled TaqMan Copy
Number Assay (Life Technology) for LAMA1 exon 3
(Hs00282410_cn), CDKN2A exon 5 (Hs03714372_cn),
and NTRK1 intron 3 (Hs05769842_cn). A 10 μl reaction
was prepared with 5 μl of KAPA PROBE-FAST qPCR
Master Mix (2X) ABI Prims (Kapabiosystems), 0.5 μl of
TaqMan assay (20X), and 10 ng of template gDNA.
Thermal cycling conditions consisted of an initial cycle
at 95 °C for 10 min, followed by 40 cycles each of 15 s
95 °C and 1 min 60 °C. Comparative cycle threshold (Ct)
values for each target gene were calculated by Bio-Rad
CFX Manager 2.1 software (Bio-Rad Laboratories Inc.)
using regression mode and relative copy number ratio
was measured by the E ΔCt method over the reference
gene LAMA1, where E is the PCR efficiency calculated
by standard curves generated from dilution series of cali-
brator gDNA, as previously described [15]. Experiments
were repeated in two independent replicates, where PCR
for each assay was performed in three internal replicates.
Diploid copy number was set as a fold change of 1; gain
of one extra genomic copy was defined when fold
change over diploid calibrator was between 1.25 and
1.75; amplification was defined as an increase in fold
change above 1.75; hemizygous deletion was determined
as a fold change between 0.75 and 0.5; homozygous de-
letion was defined as fold-change decrease below 0.5
[15, 23].
Quantitation of DNA copy number and mRNA expression
for cell lines
Total gDNA from MM cells was extracted with DNeasy
Blood & Tissue kit (Qiagen). Genomic copy number of
TrkA and CDKN2A was quantified by comparison with
gDNA of normal melanocytes (#C-024-5C; HEMaLP,
Life Technology), using the same primer set and proto-
cols as previously described for tissue samples. Relative
copy number ratio was measured by applying regression
mode, as calculated by the Bio-Rad CFX Manager 2.1
software, and the ΔΔCt method Ct for normalization of
Ct values to LAMA1 as internal reference gene [24]. The
experiment was repeated twice.
Total RNA from MM cells was extracted by using
RNeasy Plus mini Kits (Qiagen) and reverse-transcribed
using iScriptTM cDNA Synthesis Kit (Bio-Rad). The ob-
tained cDNA was subjected to real-time qPCR by Taq-
ManGene Expression Assay (Life Technologies).
Commercially available FAM-labeled TaqMan assays were
used for LAMA1 (Hs00300550_m1) and NTRK1
(Hs01021011_m1). A 10 μl reaction was prepared with 5
μl of KAPA PROBEFAST qPCR Master Mix (2X) ABI
Prims (#KK4702; Kapabiosystems, Woburn, MA), 0.5 μl
of TaqMan assay (20X), 100 ng of template cDNA, and
run on Bio-Rad CFX384 Real-Time PCR Detection Sys-
tem (Bio-Rad). PCR cycles were: 95 °C for 3 min, followed
by 40 cycles at 95 °C for 10 s and 60 °C for 30 s. Values of
Ct were calculated by Bio-Rad CFX Manager 2.1 software,
using regression mode, and ΔΔCt method was used for
expression quantification using the Ct of LAMA1 for
normalization [24]. Results were obtained as a mean of
three experiments.
Vectors and lentiviral transduction
The human TrkA gene (splice variant NTRK1-001,
RefSeq NM_001012331.1) was subcloned from the ori-
ginal pCMV5-TrkA (Addgene Plasmid 15002; ref. [25])
into SalI-XbaI sites of the doxycycline-inducible Tet-On
lentiviral vector pLenti-CMV/TO-eGFP-Puro (Addgene
Plasmid 17481; ref. [26]), by replacing the eGFP se-
quence, and the construct was verified by Sanger se-
quencing. MM cells SK-MEL-28 and G-361 were
transduced with the tetracycline-repressor expression
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vector pLenti-CMV-TetR-Blast (Addgene Plasmid
17492; ref. [26]) before transduction with pLenti-CMV/
TO-TrkA-Puro or the pLenti-CMV/TO-Puro empty
vector. Lentiviral particles were produced by co-
transfecting the transfer plasmids with packaging vector
pCMV delta R8.2 (Addgene plasmid 12263; Didier
Trono) and envelop plasmid pMD2.G (Addgene plasmid
12259; Didier Trono) into HEK-293-T cells (ICLC Inter-
lab Cell Line Collection), in a penicillin/streptomycin-
free Opti-MEM® culture medium (Life Technology), with
0.5 mg/ml Polyethylenimine (Sigma-Aldrich), based on
Trono lab protocols (http://tronolab.epfl.ch). Viral titer
in the supernatant was established at 0.5 transducing
units (TU) per reaction, as measured by SYBR Green I-
based PCR-enhanced reverse transcriptase (SG-PERT)
assay [27]. Parallel infection efficiency of pLenti-CMV/
TO-eGFP-Puro control plasmid was above 60 % at 96 h
post infection, as quantified by the GFP signal. Trans-
duced cells were selected for 6 days with puromycin 3
μg/ml (Sigma-Aldrich), starting at 48 h post-infection.
Cell treatments
Before performing the experiments, transduced cells
were allowed to adhere to the plate by growing for 16 h
in complete melanoma cell medium. Afterwards, to in-
duce TrkA expression cells were pre-treated with 500
ng/ml doxycycline (Sigma-Aldrich) for 48 h, either in
medium 2 % FBS or FBS-free medium, and doxycycline
was maintained during the entire course of the experi-
ments. To test the activation of NGF-TrkA downstream
pathways, cells were treated with 100 ng/ml β-NGF
(#PHG0126; Life Technology) for 15 min in FBS-free
medium. A dose–response curve was measured by incu-
bating the cells for 15 min in FBS-free medium with
6.25, 12.5, 25, 50, and 100 ng/ml β-NGF. To activate
NGF-TrkA signaling before phenotypic assays, cells were
treated with 100 ng/ml β-NGF for 24 h or 48 h. To spe-
cifically block the MAPK pathway, cells were incubated
with 5 μM U0126 (Promega) in the presence or absence
of NGF. To inhibit the AKT pathway, cells were incu-
bated with 25 μM LY294002 (Promega) in the presence
or absence of NGF. CEP-701 (Sigma-Aldrich) was used
at 10 μM, as a broad inhibitor of kinase signaling. Con-
trol experiments were conducted in the absence of doxy-
cycline in 2 % FBS medium or FBS-free medium plus
vehicle (DMSO). During treatment experiments, vehicle
was either water (for NGF controls) or DMSO (for kin-
ase inhibitor controls).
Western blot analysis
Cells (approximately 0.5 x 106) were harvested on ice in
lysis buffer (50 mMTris-HCL pH 8, 150 mM NaCl, 1 %
NP-40, 0.5 % sodium deoxycholate, 0.1 % SDS) supple-
mented with 1 μg/ml Pepstatina A (Sigma-Aldrich),
protease inhibitor cocktail (Sigma-Aldrich) and phos-
phatase inhibitor cocktails 1/2 (Sigma-Aldrich). After de-
termination of total protein content by the Bradford
reagent (Sigma-Aldrich), 30 μg of protein extracts were
resolved by SDS-PAGE gels and then blotted onto 0.2
μm nitrocellulose membrane (Bio-Rad). Unspecific pro-
tein binding was blocked by incubation for 1 h in 5 %
Blotto non-fat dry milk (Santa Cruz Biotechnologies
Inc.) in 0.1 % TBS-tween and membranes were incu-
bated overnight at 4 °C with primary antibodies: rabbit
anti-TrkA, 1:1000 (#06-574; Upstate); rabbit anti-
phospho (Try490)-TrkA, 1:1000 (#9141S; Cell Signaling
Technology Inc.); rabbit anti-ERK1/2, 1:2000 (sc-153;
Santa Cruz); rabbit anti-phospho-ERK1/2, 1:1000
(#4370S; Cell Signaling); rabbit anti-AKT(pan), 1:1000
(#4691S; Cell Signaling); rabbit anti-phospho-AKT1,
1:1000 (Ab66138; abcam); mouse anti-p21cip1 (sc-397;
Santa Cruz, 1:2000); mouse anti-eIF4E, 1:1000 (SC9976;
Santa Cruz); mouse anti-p53, 1:5000 (sc-377567; Santa
Cruz); mouse anti-Cyclin D1, 1: 1000 (ab101430;
Abcam); mouse anti-β-tubulin (sc-53140; Santa Cruz,
1:5000); mouse anti-α-actinin (sc-17829; Santa Cruz,
1:6000); mouse anti-GAPDH (sc-32233; Santa Cruz;
1:5000). After washing, membranes were incubated for 1
h at room temperature, with goat anti-rabbit (sc-2004;
Santa Cruz) or goat anti-mouse (sc-2005; Santa Cruz)
secondary HRP-conjugated antibodies, diluted 1:10000
in blocking solution. Membranes were then washed and
developed by using the ECL detection assay (Amersham
Biosciences). After detection of phospho-TrkA,
phospho-AKT, and phospho-ERK signals, the mem-
branes were stripped with Re-Blot Plus Mild Solution
(Merck Millipore) and re-blotted for total protein stain-
ing. Protein expression was quantified from digital im-
ages by Image Lab software (Bio-Rad), setting the global
subtraction method for background. TrkA proteins typ-
ically correspond to two WB bands: the mature cell sur-
face 140-kDa form and the immature 110-kDa form,
which is subsequently modified by glycosylation in the
ER before translocation to the membrane [28].
Cell-cycle analysis
Cells were seeded (0.4 × 105 cells/well) in a 6-well plate
and allowed to adhere for 16 h in complete medium.
After treatment, cells were centrifuged and processed
with the Cycletest™ Plus DNA Reagent Kit (BD Biosci-
ences) and incubated in Propidium Iodide (PI) labeling
solution, following the manufacturer’s indications. Cell
cycle analysis, by measuring DNA content, was per-
formed by flow cytometry using a FACS Canto II instru-
ment (BD Biosciences). FACSDiva™ Software V8.0 (BD
Biosciences) was used to quantify the distribution of
cells in each cell cycle phase: sub-G1 (dead cells), G1, S
Pasini et al. BMC Cancer  (2015) 15:777 Page 4 of 18
and G2/M. Results were displayed as the average of
three separate experiments.
Real-time proliferation analysis
Cell proliferation was monitored by the xCELLigence
RTCA DP Analyzer (Roche) for at least 48 h after treat-
ment, following manufacturer’s indications. This appar-
atus makes it possible to follow the cellular response to
treatment in real-time using electrical impedance as the
readout. The continuous monitoring of cell viability by
the xCELLigence system allows us to distinguish
between cell death and reduced proliferation [29]. Cells
(5 × 103 cells/well) were seeded into E-plates 16 (Acea
Biosciences Inc.) and impedance was continuously
recorded in 15 min intervals until the end of the experi-
ment. Cell index (CI) values, derived from the measured
impedances, were acquired by the RTCA Software V1.2
(Roche) and exported to Microsoft Excel for
normalization of data of each single well to the first
measurement after starting the treatment. Statistical ana-
lysis and graphical representation of data were per-
formed by the Prism GraphPad Software V5.0
(GraphPad Software Inc., La Jolla, CA, USA). Data dis-
played in the graphs is the average value of three bio-
logical replicates, each consisting of two technical
replicates.
Cell number quantification, proliferation assay and
detection of apoptosis
To assess proliferation after treatment by measuring the
amount of newly synthetized DNA, cells were plated in
a 96-well plate (5 × 103 cells/well) and the Click-iT® EdU
cell proliferation assay (Life Technologies) was used fol-
lowing the manufacturer’s instructions. Cells were incu-
bated with 10 μM of the nucleoside analog EdU for 2 h
and immediately fixed in 4 % formaldehyde and perme-
abilized. To detect apoptosis, cells were stained for 1 h
at room temperature with anti-active-caspase-3 anti-
body, 1:600 (ab13847; Abcam) followed by goat anti-
rabbit secondary antibody staining, Alexa Fluor® 488,
1:1000 (#A-11070; Life Technologies), for 1 h at room
temperature. The total DNA was stained with Hoechst
33342 (Life Technologies) and used for quantifying the
absolute number of cells present in the plate. Quantifica-
tion of fluorescent cells that incorporated Hoechst
33342, EdU or were stained for caspase-3 was carried
out by using the Operetta® High Content Imaging Sys-
tem equipped with the Harmony software (PerkinElmer
Inc.). Fractions of EdU labeled cells were calculated
based on Hoechst signal. Three independent experi-
ments, with two internal replicates, were performed for
each condition.
Statistical analysis
All statistical analysis were performed by Prism Graph-
Pad Software V5.0 (GraphPad Software Inc.) except for
the association of copy number amplifications, detected
by aCGH, with tumor thickness, which was calculated
by the Mann–Whitney test in the R software environ-
ment for statistical computing. Detailed methods for the
identification of CNAs from the aCGH data are provided
in ref. [15]. The Mann–Whitney test was used to evalu-
ate the association between MM thickness and copy
number levels of TrkA derived from aCGH and genomic
qPCR analysis. Pearson’s correlation coefficient was use
to assess correlation between the aCGH copy number
log2 ratio and the log2 of the qPCR fold changes of
TrkA. Spearman’s correlation test was used to evaluate
the correlation between TrkA copy number and mRNA
expression data extracted from publically available re-
sources: Cancer Cell Line Encyclopedia (CCLE, http://
www.broadinstitute.org/ccle/home) and The Cancer
Genome Atlas data (TCGA, http://www.cbioportal.org/
index.do; ref. [30, 31]).
The Kaplan-Meier method and log-rank test were used
to assess the difference in overall survival and metastatic
outcome between TrkA-amplified patients and TrkA-
diploid patients. One-way ANOVA test, followed by
Tukey’s post-test to compare two groups, was performed
to explore differences of proliferation rates in the xCEL-
Ligence proliferation assay. Student’s t test (two-tailed,
unpaired) was used to compare means for all other stat-
istical analyses. Results for cellular experiments are given
as the mean of three independent experiments; p values
were considered significant when lower than 0.05.
Results
Identification of TrkA amplification in MM patients
Genomic amplification is a potential indicator of onco-
gene activation. To identify candidate oncogenes that
participate in melanomagenesis, we retrospectively ana-
lyzed 31 primary MM samples, previously characterized
for genomic profiles with aCGH (GSE45354; ref. [15]),
by exploring the association between genomic amplifica-
tion and tumor thickness, a first-line clinical parameter
of MM progression. Altogether, we detected 40 minimal
common amplification hotspots over 12 chromosomes,
consisting of average 5.7 amplicons per MM genome
with a mean size of 0.47 Mb. A total of 994 unique genes
are present within the amplicons, preferentially localized
in 1q21–23, 6p21–25, 8q24, 19p13, and 20q13 (Fig. 1a
and Additional file 1: Table S2). This produces a pattern
similar to those observed in previous studies [18, 20], and
supports the validity of our analysis.
Among the most frequently amplified loci identified in
the MM genome, the 1q23.1 hotspot (amplified in 16 %
of patients) had the strongest statistical association
Pasini et al. BMC Cancer  (2015) 15:777 Page 5 of 18
Fig. 1 (See legend on next page.)
Pasini et al. BMC Cancer  (2015) 15:777 Page 6 of 18
(Mann–Whitney U test: p = 0.03) with primary tumor
thickness (Additional file 1: Table S2). This minimum
common region of amplification displayed a characteris-
tic profile of segmental gain, as defined by aCGH, that
spanned over 280 kb (Fig. 1b), supporting the hypothesis
of tumorigenic selective pressure. Analysis of correlation
showed that tumor thickness proportionally increased in
those primary tumors undergoing allele duplication
(Mann–Whitney U test: p = 0.03) or amplification
(Mann–Whitney U test: p = 0.03) of the 1q23.1 hotspot,
compared to diploid samples (Fig. 1c). Median thickness
of MMs that harbored the 1q23.1 amplification was 4.7
mm (range 1.6–20.0 mm), compared to 3.0 mm (range
2.5–12.0 mm) when the 1q23.1 locus is duplicated, and
2.3 mm (range 1.5–3.0 mm) of those MMs that maintain
diploid 1q23.1. Therefore, we closely examined the genes
localized in the 1q23.1 amplicon for a potential role in
MM oncogenesis. Of the seven protein-coding genes
and one miRNA gene present in the minimal common
region of the same amplicon, the TrkA gene was the
most promising candidate for driving segmental amplifi-
cation within the 1q23.1 region in MM, based on its im-
portant role in melanocyte biology and known
involvement in cancer. Interestingly, the minimal seg-
mental alteration included only part of the long non-
functional isoform (NTRK1-004) of the NTRK1 gene
[GenBank: Y09028] while it fully encompassed the entire
functional isoform (NTRK1-001), which starts from a
secondary transcription site and encodes for the canon-
ical receptor tyrosine kinase TrkA (Fig. 1b). This obser-
vation may suggest the presence of a 5′ breakpoint
occurring inside the NTRK1 gene and localizing imme-
diately upstream to the transcription start site of the
functional isoform of TrkA.
TrkA amplification associates with MM progression and
negative patient outcome
To validate the discovery of the TrkA-1q23.1 amplicon
as a potential hotspot associated with tumor progression,
we performed genomic qPCR in a cohort of 64 primary
MMs, including 29 samples previously analyzed by
aCGH (we were able to perform qPCR only on 29
samples of the 31 included in the aCGH set, because of
the limited amount of starting gDNA). This analysis re-
vealed that TrkA amplification is a frequent event (50 %
of the patients) in MM (Fig. 2a). The accuracy of our
analysis was tested by comparing the aCGH data
(Additional file 1: Table S3) to the results obtained by
genomic qPCR (Additional file 1: Table S4): for each
sample, the qPCR copy number fold changes (sample/
diploid control) were converted to log2 values for direct
comparison with the mean values of log2 ratios from
aCGH signals. The directions of copy number changes
were consistent for 27 samples out of 29, showing good
concordance between the two methods (Fig. 2b). Be-
sides, as a control for experimental reliability, we per-
formed the same analysis on the CDKN2A gene, which
is a major marker of MM-associated CNAs [9], obtain-
ing results in agreement with what expected from the
literature (Additional file 2: Figure S1).
Next, we examined the association of the TrkA copy
number measured by genomic qPCR with the MM
thickness and found that primary tumors with TrkA
amplification were significantly thicker (p = 0.02) com-
pared to tumors with diploid TrkA (Fig. 2c). Samples
were then verified for the association of clinical out-
comes with copy number status (with or without ampli-
fication) of TrkA, by using Kaplan–Meier analysis.
Patients presenting TrkA amplification showed earlier
recurrence of metastasis to distant organs than those
with diploid TrkA, as detected by qPCR (Fig. 2d; hazard
ratio = 0.30; 95 % confidence interval = 0.09–0.98; log-
rank test, p = 0.046). Patients with TrkA amplification
also showed a tendency to survive less relative to TrkA-
diploid patients (Fig. 2e), although the difference in over-
all survival was statistically not significant (hazard ratio
= 0.54; 95 % confidence interval = 0.14–2.07; log-rank
test, p = 0.37). Taken together, these results confirm our
findings in the discovery set of array CGH, giving indica-
tion of TrkA amplification as a specific oncogenic event
occurring in MM that correlates with the aggressiveness
of the primary tumor.
We tried to substantiate our hypothesis through the
analysis of public resources. By looking at The Cancer
(See figure on previous page.)
Fig. 1 Identification of TrkA-1q23.1 genomic amplification in MM patients. a, hotspots of 40 minimum common amplifications (red) in primary MM
genome, detected by aCGH across 31 patient samples, are plotted along their corresponding chromosome position and proportionally to the
respective amplicon size. Detailed genomic information of hotspots is provided in Additional file 1: Table S2. b, schematic segmental gain profile within
the 1q23.1 region (spanning ~2.5 Mb), as defined by aCGH, is represented with horizontal bars, each denoting the copy number status of an individual
MM patient. MM samples with increasing primary tumor thickness are at the top (for details see Additional file 1: Table S4). Genomic amplifications are
depicted in red. The black boundaries delineate the extent of the minimal common amplification (genomic coordinates chr1:156826196 to
chr1:157106439). The graphical layout of the genes localized in the minimal amplification is based on the Ensembl release 75.37 of the human genetic
map. The region of minimal common amplification extends over ~280 kb and retains the functional transcript of the NTRK1 gene [GenBank: Y09028],
NTRK1-001 (red and inset), which codes for TrkA protein. For each panel, the corresponding scale of genomic positions (in Mb) is indicated. c, box and
whiskers graph showing the association of TrkA-1q23.1 minimal amplification and tumor thickness in primary MM samples analyzed by aCGH (n = 31;
Mann-Whytney U test: *, p < 0.05). Dipl, diploid copy number; Dup, duplication; Amp, amplification
Pasini et al. BMC Cancer  (2015) 15:777 Page 7 of 18
Fig. 2 TrkA amplification associates with primary MM thickness and metastatic outcome. a genomic qPCR detection of copy number levels of TrkA gene in
primary MM samples (n = 64), reported as fold-change over a diploid control of pooled healthy DNA (mean ± SD of n = 2 independent experiments, each of
three replicates). Two additional samples of benign nevi were used as further accuracy control for diploidy. Samples are arranged according to increasing
tumor thickness. Genomic amplification is depicted in red. b comparison of TrkA copy number levels for 29 primary MM samples from the aCGH dataset
showing significant correlation between aCGH and qPCR. Log2-transformed fold changes (sample/control) of qPCR results are plotted with the corresponding
aCGH log2 ratio mean values (Pearson’s correlation: p < 0.01; Pearson’s correlation coefficient, r = 0.5). c box and whiskers graph of the association between
TrkA amplification and tumor thickness in primary MM samples analyzed by genomic qPCR (n = 64; Mann-Whytney U test: *, p < 0.05). d Kaplan–Meier curves
for metastasis free survival in patient cohorts with TrkA amplification (n = 32) or TrkA diploidy (n = 12), as detected by genomic qPCR of primary MM genome
(*, p < 0.05 by log-rank test). e Kaplan–Meier curves of overall survival for patients with TrkA amplification (n = 32) or diploid TrkA (n = 12), as detected by
qPCR on primary MM genome (n.s., not statistically significant by log-rank test). Dipl, diploid copy number; Amp, amplification
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Genome Atlas (TCGA) data available through the cBio-
Portal (http://www.cbioportal.org/index.do; ref. [30, 31]),
the TrkA gene is recurrently altered (14 % of 278 re-
ported tumor samples with RNA-seq and CNA data) in
MM, via amplification, mRNA level upregulation, and
missense mutations (Additional file 2: Figure S2A).
Cases with alterations tend to have the worse prognosis
(median month survival of 35.91) compared to cases
without TrkA alterations (median month survival of
65.87), although the difference is not statistically signifi-
cant (Additional file 2: Figure S2B).
Reconstitution of TrkA signaling blocks proliferation of
MM cells in vitro
Although histological immunostaining of TrkA has been
associated with the clinical outcome of MM [32], very
little is known about its molecular function in MM cells.
Thus, we first confirmed that genomic copy number
gain of TrkA was also present in cell lines derived from
aggressive tumors (Additional file 2: Figure S3A). How-
ever, when we checked the expression levels of TrkA we
found that, on the contrary to what expected, endogen-
ous protein and mRNA levels were basically undetect-
able in these MM cell lines, while endogenous TrkA
expression was clearly distinguishable in the positive
control (PC12 pheochromocytoma rat cells) and, to a
certain extent, also in normal human melanocytes
(Additional file 2: Figure S3B and S3C). To confirm this
finding we surveyed the data available at the Broad-
Novartis Cancer Cell Line Encyclopedia (CCLE, http://
www.broadinstitute.org/ccle/home) and found that the
log2 mRNA levels of TrkA are indeed quite low (median
log2 = 3.8; CI: 3.8–4.0), although a fraction of these cells
lines show gain or amplification of the TrkA locus
(Additional file 1: Table S5). This observation brought to
the hypothesis that the contribution of TrkA overexpres-
sion (acquired through genomic gain) to the initial pro-
gression of the primary tumor might be negatively
selected afterwards (by down-regulating gene expres-
sion), as it is reflected in our cell lines derived from ad-
vanced MMs. Analysis of CCLE cell line data revealed
that TrkA mRNA levels and genomic amplification are
indeed not correlating (Additional file 2: Figure S2C;
Spearman r = 0.080). As well, we were not able to detect
any significant correlation between TrkA mRNA and
copy number levels in tumor samples collected by
TCGA at the cBioPortal (Additional file 2: Figure S2D;
Spearman r = 0.086) and listed in the Additional file 1:
Table S6.
To further explore our hypothesis, we reconstituted
NGF-TrkA signaling by controlled expression of TrkA
under a doxycycline-dependent promoter and NGF ad-
ministration in two of the MM cell lines previously tested:
SK-MEL-28 and G-361 (Additional file 2: Figure S3D).
Expression of TrkA was induced for 48 h, followed by 24
h of NGF stimulation. Interestingly, we observed that
addition of NGF caused dramatic morphological changes
of MM cells transduced with the TrkA-inducible system
(SK-MEL-28-TrkA and G-361-TrkA) only upon activation
of TrkA expression by doxycycline, in comparison with
the same cells in the absence of doxycycline or the empty-
vector controls (SK-MEL-28-E and G-361-E), as shown in
Fig. 3a and b. This phenotype, exclusively dependent on
the activation of the NGF-TrkA axis, became visible early
after treatment, reaching its peak at 8 to 24 h, and con-
sisted in a conspicuous intracellular vacuolization and cell
shrinkage. Cell cycle analysis revealed that this
phenomenon was accompanied by proliferation arrest,
resulting from a reduction of the S-phase cell population
of MM cells expressing TrkA upon NGF treatment, again
relative to the empty vector transduced cells or doxycyc-
line untreated cells. Block of cell cycle was especially
marked for the SK-MEL-28-TrkA cell line, experiencing
an increase (p = 0.03) of the G2 fraction (Fig. 3c), while
the G-361-TrkA cell line showed a moderate increase (p =
0.07) of the G1-phase fraction (Fig. 3d). All together, these
observations are consistent with a phenotype of
checkpoint-guided inhibition of cell proliferation as a con-
sequence of oncogene-induced growth arrest.
MAPK and AKT mediate opposite effects during
proliferation arrest of MM cells induced by NGF-TrkA
signaling
The MAPK and AKT pathways are two major effectors
of NGF-induced TrkA signaling in different cell models
[1], although this function has not been elucidated for
MM cells yet. Our data showed that short stimulation
(15 min) with NGF could induce phosphorylation of
TrkA along with activation of ERK1/2 (p42/p44 MAPK)
and AKT1 kinases over the basal levels in the MM cell
lines SK-MEL-28-TrkA and G-361-TrkA, previously
prompted by doxycycline to express TrkA (Fig. 4). This
observation indicated that both ERK and AKT were
downstream kinases to NGF-TrkA signaling in MM
cells, although ERK showed a sustained basal state of en-
dogenous phosphorylation, while in a dose–response
assay (Additional file 2: Figure S4) AKT phosphorylation
seemed to be more dependent on NGF-TrkA activation.
Hence, we wanted to examine the effects of specific in-
hibition of MAPK and AKT signaling during a pro-
longed period of time and test if these two pathways
may have a role in the proliferation arrest phenotype we
observed in the presence of active NGF-TrkA signaling.
Cells were incubated with doxycycline for 48 h to induce
TrkA expression before the 24 h treatment with kinase
inhibitors. As expected, selective inhibition of ERK or
AKT basal activity by the respective upstream inhibitors
U0126, which blocks mitogen-activated protein kinase-
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Fig. 3 (See legend on next page.)
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Fig. 4 Activation of MAPK and AKT downstream to NGF-TrkA signaling in MM cells. SK-MEL-28 and G-361 cells, stably transduced with
doxycycline-inducible TrkA-vector or empty vector were incubated for 48 h with vehicle (DMSO) or doxycycline (500 ng/ml) in FBS-free medium.
Cell extracts were collected at 15 min post-stimulation with vehicle or NGF (100 ng/ml) and subjected to Western blotting using the indicated
antibodies. Anti-β-tubulin was used as loading control for TrkA and ERK; anti-GAPDH was used as loading control for ATK. The protein markers in
kDa are estimated from the molecular weight standard. Images are representative of n = 3 experiments. Dox, doxycycline; E, empty vector
(See figure on previous page.)
Fig. 3 Activation of NGF-TrkA signaling induces cell cycle arrest of MM cells. a and b, representative images showing the morphology of MM cells
upon TrkA ectopic expression and following activation by NGF. Stably transduced cells with either doxycycline-inducible vector (SK-MEL-28-TrkA
and G-361-TrkA) or empty vector (SK-MEL-28-E and G-361-E) were incubated for 48 h with or without doxycycline (500 ng/ml) and next treated
with NGF (100 ng/ml) or vehicle for 24 h in 2 % FBS medium. Images were obtained using phase-contrast microscopy from four independent
experiments. Arrowheads indicate cells displaying distinctive morphological changes of oncogene-induced type growth arrest of intracellular
vacuolization and cell shrinkage. c and d, cell proliferation of SK-MEL-28-E/TrkA and G-361-E/TrkA was tested by cell-cycle assay performed using
DNA staining with propidium iodide and FACS analysis. Cells were incubated with or without doxycycline (500 ng/ml) for 48 h and then
stimulated with NGF (100 ng/ml) for 24 h or vehicle treated. Bar graphs represent frequency of cell-cycle phases as the mean ± SD of n = 3
independent replicates (Student’s t test: *, p < 0.05 compared to vehicle control). Dox, doxycycline
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kinase (MEK), or LY294002, which blocks phos-
phatidylinositol 3-kinase (PI3K), induced a visible change
in cell viability compared to vehicle control, although it
did not affected substantially the total cell number (Fig. 5a
and b; Additional file 2: Figure S5B). Inhibition of broad
receptor-tyrosine-kinase activity by CEP-701 induced in-
stead a massive cell death, possibly due to generalized
block of cellular signaling; therefore we used treatment
with CEP-701 as a general cell death control. Inhibition of
the AKT pathway in the presence of NGF apparently pro-
moted a further increase in cell loss compared to the
LY294002 treatment alone (SK-MEL-28-TrkA, p = 0.002;
G-361-TrkA, p = 0.03), suggesting that AKT was not re-
sponsible for the cell proliferation arrest observed after
Fig. 5 Proliferation arrest promoted by NGF-TrkA signaling in MM cells is enhanced after AKT pathway inhibition and dampened by the inhibition
of MAPK pathway. a and b, stably transduced MM cells with doxycycline-inducible TrkA-vector (SK-MEL-28-TrkA and G-361-TrkA) were incubated
for 48 h in 2 % FBS medium with doxycycline (500 ng/ml) and next treated with vehicle (DMSO), MAPK pathway inhibitor U0126 (5 μM), AKT
pathway inhibitor LY294002 (25 μM), or the broad range receptor kinase inhibitor CEP-701 (10 μM), in the presence or absence of NGF (100 ng/
ml) for 24 h in 2 % FBS medium. Images of morphological changes induced by treatment are representative of three independent experiments
and were obtained using phase-contrast microscopy from cells growth in 96-well plate. c and d, cell proliferation or apoptosis of 48 h
doxycycline-induced (500 ng/ml) SK-MEL-28-TrkA and G-361-TrkA cells, was measured 24 h post-treatment with NGF or indicated kinase inhibitors
(as above), by using Click-iT EdU cell-proliferation assay or caspase-3 immunostaining, respectively. Images were acquired and quantified by the
Operetta High Content Imaging System and cell count reported as fraction over total cell number (mean ± SD of n = 3 independent replicates;
Student’s t test: **, P < 0.01; ***, P < 0.001). e and f, proliferation of SK-MEL-28-TrkA and G-361-TrkA cells, pre-induced with doxycycline (500 ng/ml) for
48 h in 2 % FBS medium, was monitored real-time by using the xCELLigence system. Cells were then maintained for 48 h in 2 % FBS medium with
NGF (100 ng/ml) in the presence or absence of kinase inhibitors U0126 (5 μM), LY294002 (25 μM), CEP-701 (10 μM) and compared to vehicle control.
Relative cell proliferation was measured by cell index (CI) and normalized at the beginning of treatment. Error bars are showed as SD below the
trend-line of the mean from three independent biological replicates, each consisting of two internal replicates. One-way ANOVA was performed
followed by Tukey’s post-test (***, P < 0.001). Dox, doxycycline
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activation of NGF-TrkA signaling, but instead could medi-
ate a pro-proliferative stimulus downstream to the NGF-
TrkA pathway (Fig. 5a and b; Additional file 2: Figure
S5A). On the contrary, inhibition of the MAPK pathway
in response to NGF-TrkA activation had no significant in-
cremental effects over U0126 alone, but rather seemed to
partially rescue cell viability, as compared to NGF stimula-
tion (SK-MEL-28-TrkA, p = 0.01; G-361-TrkA, p =
0.0004), indicating that MAPK could be responsible for
the anti-proliferative action of NGF-TrkA signaling (Fig. 5a
and b; Additional file 2: Figure S5A). Treatment with NGF
produced no effects when TrkA was not expressed, in the
SK-MEL-28-E and G-361-E cells (Additional file 2: Figure
S5). These phenotypic observations gave a first indication
that MAPK and AKT might mediate different signaling
downstream to the NGF-TrkA axis. To investigate if the
effects due to inhibition of the NGF-TrkA downstream ki-
nases were directly associated with cell proliferation or
apoptosis, we performed EdU incorporation, which stains
cells in active S-phase replication, and caspase-3 activity
detection assay. First we observed that, independently
from active NGF-TrkA signaling, inhibition of the MAPK
or AKT pathway blocked basal proliferation of MM cells,
without however inducing apoptosis (Additional file 2:
Figure S6). Activation of NGF-TrkA signaling in SK-MEL-
28-TrkA and G-361-TrkA cells led to a severe reduction
in proliferation with marginal effects on caspase-3 activity
only in SK-MEL-28-TrkA, confirming that the decrease in
cell number we previously observed was due to lowered
proliferation rate rather than increased apoptosis (Fig. 5c
and d). Simultaneous addition of U0126 with NGF re-
sulted in a strongly sustained proliferation (observed in
both cell lines), compared to cells growing in the presence
of U0126 alone (SK-MEL-28-TrkA, p = 0.0006; G-361-
TrkA, p = 0.0002), suggesting a partial counteraction of
the growth arrest effect, induced by the activation of
NGF-TrkA signaling, when the MAPK cascade is blocked
(Fig. 5c and d). On the opposite, addition of LY294002 to
SK-MEL-28-TrkA cells treated with NGF induced a fur-
ther decrease of cell proliferation (SK-MEL-28-TrkA, p =
0.005; G-361-TrkA, p = 0.08), along with an up-regulation
of the apoptotic signal over NGF-untreated cells (particu-
larly marked in SK-MEL-28-TrkA cells; Fig. 5c), indicating
that AKT function could be crucial for mediating the pro-
survival branch of the NGF-TrkA pathway. Results for
empty vector controls and doxycycline untreated cells
confirmed that these effects were induced only in the
presence of active NGF-TrkA signaling (Additional file 2:
Figure S5). To further validate that TrkA regulates the
NGF-induced MAPK and AKT pathways with differential
outcomes on MM cell proliferation we used impedance-
based monitoring of cell proliferation/viability in time-
lapse, whose readout correlates very well with cell amount.
Results confirmed that AKT and MAPK pathways had
an NGF-TrkA independent basal activity in MM cells:
blocking both pathways results in a pronounced slow-
down of cell proliferation, as compared to controls
(Additional file 2: Figure S7). When NGF was added
to doxycycline-activated SK-MEL-28-TrkA and G-361-
TrkA cells, therefore reconstituting NGF-TrkA signal-
ing, it induced a rapid decrease in cell proliferation,
confirming our previous observations (Fig. 5e and f ).
Concomitant inhibition of the AKT pathway in the
presence of NGF determined an even more pro-
nounced proliferative reduction in both cell lines, al-
though to a greater extent in SK-MEL-28-TrkA cells
(Fig. 5e), as compared to NGF + U0126 treated cells
and NGF treatment alone (Fig. 5e and f ). On the
contrary, inhibition of the MAPK pathway slightly de-
layed the decrease of cell proliferation induced by
NGF-TrkA signaling (Fig. 5e and f ). Taken together,
these results indicate that both the MAPK and the
AKT pathways participate in maintaining basal prolif-
eration of MM cells. When NGF-TrkA signaling is
activated, MM cells enter a rapid proliferative arrest
(without induction of apoptosis). However, the down-
stream AKT pathway is mainly required to sustain
proliferation and survival (inhibiting AKT following
NGF-TrkA stimulus accentuates cell lost and growth
arrest), while the MAPK pathway may also have di-
vergent functions and mediate an anti-proliferative
signaling in response to NFG-TrkA activation (cell
viability is improved when MAPK is inhibited follow-
ing the NGF-TrkA stimulus).
MAPK induces up-regulation of p21cip in response to
NGF-TrkA signaling in melanoma cells
It is known that prolonged activation of the MAPK
pathway specifically mediates oncogene-induced growth
arrest in several cancer models [11]. Although BRAF is
the main mediator of this anti-proliferative response in
MM [33], it is still not clear whether kinase membrane
receptors can start these events. We investigated more
in detail the molecular activity of the MAPK pathway
downstream to NGF-TrkA signaling in doxycycline-
induced SK-MEL-28 and G-361 cells, by using anti-
phospho-TrkA and anti-phospho-ERK antibodies in
Western blotting. First, we monitored the protein ex-
pression levels of known downstream targets of the
TrkA-MAPK pathway that could be involved in cell
cycle and proliferation of MM cells, including cyclin D1,
p53, eIF4E, and p21cip1 (Additional file 2: Figure S8).
Among this subset of genes, we were able to detect a
consistent increase in p21cip1 protein levels in response
to NGF stimulation of MM cells expressing TrkA, but
not in unstimulated cells or empty vector controls. Since
the anti-proliferative function of the MAPK pathway is
primarily effected through upregulation of p21cip1 [33, 34],
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we blocked the MAPK cascade by incubating the cells
with U0126 to observe consequent changes in p21cip1 ex-
pression. After 24 h, U0126 reduced to basal level the
phosphorylation of ERK that was triggered by TrkA acti-
vation in the presence of NGF, while completely suppress-
ing MAPK signaling in the absence of NGF (Fig. 6a).
Protein levels of transduced TrkA were also increased
upon NGF stimulation: this effect may be a consequence
of a regulatory loop downstream to prolonged TrkA-
kinase signaling, not observed instead after short stimula-
tion (Additional file 2: Figure S4). The up-regulation of
p21cip1 induced by the activation of MAPK via NGF-TrkA
signaling was clearly prevented when U0126 was con-
comitantly added to the culture (Fig. 6a). As expected, we
did not detect up-regulation of ERK phosphorylation and
elevation of p21cip1 level downstream to NGF when cells
were not induced by doxycycline to express TrkA (Add-
itional file 2: Figure S9). Parallel analysis of cell morph-
ology showed that, in the presence of active NGF-TrkA
signaling, inhibition of the MAPK pathway by U0126 par-
tially rescued the cell loss and vacuolization phenotypes
that followed from NGF stimulation of doxycycline-
induced SK-MEL-28-TrkA and G-361-TrkA cells (Fig. 6b).
No changes were observed instead for doxycycline un-
treated cells and empty vector controls, confirming that
these events were specifically dependent on NGF-TrkA
signaling (Additional file 2: Figure S10). These results
show a direct involvement of the MAPK pathway in re-
sponse to sustained NGF-TrkA signaling to attenuate the
tumorigenic phenotype of MM cells by promoting prolif-
eration arrest and support a model of negative feedback
loop that may act through the up-regulation of the p21cip1
tumor suppressor (Fig. 6c).
Discussion
Although oncogenic activation of TrkA is traditionally
associated with chromosomal translocation [6], gain
and amplification of the genomic region 1q23.1,
where the TrkA locus is located, may also occur at
elevated frequency in a variety of cancers [20, 35].
Here, taking advantage of our MM panel of high-
resolution copy number data [15], we could show, for
the first time to our knowledge, that the amplification
of TrkA may represent an important event contribut-
ing to primary MM oncogenesis. Across 40 amplicons
detected in the genome of MM patients, TrkA-1q23.1
amplification was the most significantly associated
with increased thickness of the primary tumor (Fig. 1).
This finding indicates that TrkA signaling may be re-
quired for the onset of MM, when the tumor starts
invading deeper in the skin. Precisely, the minimal
amplification breakpoints created a hotspot that pre-
served the functional isoform of the gene encoding
for the complete tyrosine-kinase receptor (Fig. 1b). As
recently discovered, constitutive activation of TrkA is
particularly common in spitzoid melanocytic lesions
through coiled-coil fusion of the kinase domain [19].
The presence of multiple recombination sites span-
ning several TrkA exons [19] may reflect a biological
property of the 1q23.1 region to be susceptible to
genomic instability also in MM and undergo recur-
rent amplification as alternate mechanism of onco-
genic selective pressure. This circumstance would
match a pattern common to several known onco-
genes, which can be often amplified, although prefer-
entially activated by translocation [20, 36, 37]. Thus, the
high incidence (50 % of MM biopsies) of TrkA amplifica-
tion we reported in this study (Fig. 2a) might suggest that
this is a prominent mechanism in primary MM to in-
crease TrkA gene dosage during the initial phases of
tumor formation. Next, we found that amplification of the
TrkA locus specifically correlated with the metastatic
course of MM patients (Fig. 2c). In agreement, benign
nevi do not show histological expression of TrkA while
phosphorylated TrkA levels increase significantly in pri-
mary MMs along with tumor thickness and the presence
of phosphorylated TrkA in MM biopsies correlates with
decreased overall survival [32]. In accordance with these
previous histological data, the importance of NGF sig-
naling in melanocyte biology [7], and its proved in-
volvement in oncogenic pathways [4, 5], TrkA gene
seems the most promising candidate for driving seg-
mental amplification of the 1q23.1 region in MM, al-
though we cannot exclude the possibility that the
other genes (INSRR, PEAR1, LRRC71, MIR765, ARH-
GEF11, ETV3L, ETV3) within the 1q23.1 minimal
common amplification could also participate in mela-
nomagenesis. However, we did not find any relevant
associations between the expression of these genes
and MM clinical attributes when querying the public
resource cBioPortal (data not reported).
Although it has been clearly shown that p75NTR, the
cognate receptor of TrkA, is important for regulating
the tumorigenic properties of MM cell lines [38, 39], dir-
ect evidences of TrkA involvement in MM cell behavior
and melanomagenesis are lacking. Our study revealed
that the induction of TrkA expression in MM cells fol-
lowing NGF stimulation significantly affects proliferation
by blocking the cells in S-phase and provoking cata-
strophic vacuolization (Fig. 3), a phenomenon that is
characteristic of oncogene-induced growth arrest [40].
However, NGF treatment of TrkA-expressing cells, while
provoking rapid proliferation arrest, was not sufficient to
promote complete cell death (Fig. 5), suggesting this
anti-proliferative effect is only partial. As the NGF-TrkA
signaling is classically implicated in MAPK and AKT ac-
tivation [1] and TrkA overexpression stimulates both
cascades in other tumor cells [41], we first verified that
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the two pathways are also activated downstream to
NGF-TrkA signaling in MM cells (Additional file 2:
Figure S4). Then we tested the effects of the inhibition
of these two pathways on MM cell viability and prolifer-
ation. While both the MAPK and AKT pathways seemed
to be important for sustained basal proliferation rate,
Fig. 6 Induction of MAPK by NGF-TrkA signaling in MM cells results in increased expression of p21cip1. a MM cells (SK-MEL-28 and G-361), stably
transduced with doxycycline-inducible TrkA-vector or empty vector, were incubated in 2 % FBS medium for 48 h with doxycycline (500 ng/ml) to
induce ectopic TrkA expression and then treated for 24 h in 2 % FBS medium with vehicle, NGF (100 ng/ml), MAPK pathway inhibitor U0126
(5 μM), or NGF (100 ng/ml) coupled with U0126 (5 μM). Cell extracts were collected 24 h post-treatment ad subjected to Western blotting using
the indicated antibodies. The protein markers in kDa are estimated from the molecular weight standard. Bar graphs show quantification of the
intensity of the bands, compared to β-tubulin (phospho-ERK and phospho-TrkA) and GAPDH (p21cip1) loading control and to the relative
untreated sample (set to 1). Data are expressed as mean ± SD of n = 3 experiments. b representative images obtained by phase-contrast
microscopy from the same plate used for Western blotting, at 24 h after treatment. Arrowheads point at cells displaying morphological changes
that are indicative of oncogene-induced growth arrest. c schematic model of our interpretation of the results: TrkA amplification in primary MM
samples may be predictive of unfavorable patient outcome, correlating with increased primary tumor thickness and distant metastasis; in some
circumstances, NGF-TrkA oncogenic signaling can couple with proliferation-arrest response that is mediated through p21cip1 up-regulation
induced by MAPK, as suggested through selective inhibition of downstream MAPK or AKT pathways in MM cell line models. Dox, doxycycline; E,
empty vector
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inhibition of AKT activation specifically produced an
additive effect to NGF-TrkA stimulation by enhancing
cell loss (Fig. 5). On the contrary, treatment with an in-
hibitor of the MAPK pathway resulted in a partial recov-
ery from cell proliferation arrest induced by NGF-TrkA
activation (Fig. 5). These observations are in line with
previous reports, where both MAPK and AKT are
required for maintaining proliferation but specific sup-
pression of AKT signaling completely abolishes the
tumorigenic capacity of MM cells [42], while MAPK
possesses a dual role of promoting proliferation on one
side and enhancing anti-proliferative feedback on the
other side [11, 33, 43].
It is generally accepted that oncogene-induced pro-
liferation arrest may act through various mechanisms
that culminate in MAPK overactivation [11, 44]. Here,
we demonstrated that NGF is essential for prompting
MAPK activity via TrkA phosphorylation in MM cells
(Figs. 4 and 6). In these circumstances, activation of
MAPK is associated with an increased expression of
the p21cip1 protein, which is instead attenuated when
MAPK signaling is inhibited (Fig. 6). Accordingly,
addition of a MAPK inhibitor produced a visible ab-
rogation of the vacuolization phenotype triggered by
active NGF-TrkA signaling in MM cells (Fig. 6).
These findings are similar to what previously shown
in non-melanoma cells where apoptotic cell death is
enhanced by MAPK activation after overexpression of
TrkA [45–47]. Although abrogation of p16ink4A func-
tion is the most common alteration that may lead to
bypass the anti-proliferative control in MM [48], we
showed here that in the absence of the p16ink4A gene,
as in our melanoma cell model, MAPK can induce a
secondary mechanism of feedback protection that
might go through p21cip1 up-regulation, which dir-
ectly blocks MM cells at the S-phase checkpoint, as
supported by previous evidence [33, 34]. Moreover,
the MM cell lines investigated in our study were de-
rived from advanced-stage MMs and harbor the
BRAFV600E constitutive-activating mutation, which
could give predisposition to oncogene-induced growth
arrest when MAPK is over-induced through alterna-
tive signaling [11, 49]. Importantly, proliferation arrest
derived from constitutive stimulation of MAPK by
BRAF is an intrinsic property of melanocytes and
melanoma cells and is the pivotal mechanism to stop
oncogenic progression in nevi, a type of benign mela-
nocytic tumors [12, 50, 51]. Although, the overall ex-
pression of TrkA in MM biopsies correlates with
worst prognosis, phosphorylated TrkA is detected in a
considerably smaller fraction of metastatic MMs com-
pared to the primary samples [32], suggesting that activa-
tion of TrkA signaling might be important for the early
onset of the tumor and might undergo down-regulation
once the tumor becomes metastatic. Further experiments
would be required to substantiate this hypothesis. How-
ever, when we investigated public datasets we did not find
any significant difference between TrkA mRNA expres-
sion in primary MMs versus metastatic MMs (data not
shown). As well, expression of TrkA does not substantially
differ in earlier compared to later MM stages (Additional
file 2: Figure S2E).
The proposed dual function of TrkA in MM, acting
in an oncogenic or in a tumor suppressor like mode,
is similar to that of the melanocyte-specific protein
MITF, which acts downstream to MAPK [51]. But,
more significantly, a dual behavior of TrkA is particu-
larly evident in neuroblastoma, a tumor of neural
crest cell precursors [52]. In neuroblastoma patients,
TrkA is initially gained and its overexpression is
found mainly at lower stages and younger age at diag-
nosis [4]; in neuroblastoma cells instead, TrkA activa-
tion decreases proliferation via MAPK induction and
induces anti-oncogenic response [46]. In the model
depicted in Fig. 6c, we hypothesize that acquisition of
TrkA amplification may arise early during melanoma-
genesis and contribute to the initial phases of onco-
genic development, correlating with increased primary
MM thickness. Primary tumors that present TrkA
amplification show also greater association with dis-
tant organ metastasis. A multifaceted crosstalk be-
tween MAPK and AKT pathways downstream to
NGF-TrkA signaling may then reflect different pro-
pensity of the MM cell to metastasize. In this
context, oncogene-induced growth arrest de facto rep-
resents a barrier to tumor progression and conse-
quently MM derived cell lines have bypassed this
impediment. Reintroduction of active NGF-TrkA sig-
naling may reimpose protective feedback mechanism
by engaging p21cip1-dependent growth arrest via hy-
peractivation of MAPK.
Conclusions
We identified TrkA as a candidate oncogene in MM that
associates with clinical features of worst prognosis. We
hypothesize that TrkA genomic amplification can pro-
mote tumor proliferation during the early phase of MM
invasion, as indicated by the association with increased
tumor thickness. Experiments in MM cells suggest that
both the MAPK and AKT pathways may mediate this
oncogenic propensity. At the same time, however, as re-
ported for other tumor models, overactivation of the
MAPK pathway in MM cells can induce a feedback pro-
tective effect against oncogenic growth, while the ATK
pathway is mainly involved in stimulating proliferation
downstream to NGF-TrkA signaling. Although the
characterization of TrkA amplification in metastatic
samples is missing and more detailed insights are
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required to understand the oncogenic potential of TrkA
in normal melanocytes and MM cells with distinct mo-
lecular background, our observations identified a previ-
ously unknown association between TrkA function and
MM development relying on TrkA amplification. Fur-
thermore, our study emphasizes the dual role of MAPK
signaling in promoting MM cell development on one
side, and in inducing feedback proliferation arrest on the
other side. These findings reinforce the current idea of
exploiting physiological pathways promoting growth ar-
rest for more effective cancer treatment [9, 13].
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